Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD

Epigenetics in CKD Rationale for BET inhibition an emerging therapeutic mechanism in renal disease and CVD
    10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Louise Nordfors - Stockholm, Sweden
    • Overview

      Louise Nordfors describes several epigenetic mechanisms that have been described to be dysregulated in human disease and the rationale for BET protein inhibition to treat CV and renal disease.

    • Educational information

      This lecture was part of a CME accredited symposium: Epigenetics in CKD & CVD: A potential breakthrough therapy? held at ERA-EDTA in Copenhagen, Denmark.

    • Faculty

      Louise Nordfors, PhD - Senior researcher at Renal Medicine, Karolinska University Hospital and the Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden

    • Disclosures

      This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    • Funding

      Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.

      The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

    Facebook Comments


    We’re glad to see you’re enjoying PACE-CME…
    but how about a more personalized experience?

    Register for free